Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02253745 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)

A Phase 1 study of ADHD, sponsored by Vernalis (R&D).

Completed
Registry status
Phase 1
Development phase
31
Enrollment target
1
Study location

NCT02253745 is a Phase 1 study of ADHD that has completed, run by Vernalis (R&D). The registered enrollment target is 31 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02253745, a Phase 1 study of ADHD, has completed, sponsored by Vernalis (R&D).

COMPLETED
Registry status
Phase 1
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of twice daily oral doses of V81444 in adults with ADHD. Pharmacokinetics (PK) is the study of how a drug is absorbed, distributed, metabolized, and eventually eliminated by the body. Pharmacokinetics is what the body does to the drug. Blood samples will be taken throughout the study for PK analysis.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG V81444

Study Locations (1)

Kansas

  • Vince and Associates Clinical Research - Kansas City

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2013-07
Est. Completion 2014-04
Phase Phase 1

Sponsor

Vernalis (R&D)

4 total trials

What the Registry Record Tells You About NCT02253745

The ClinicalTrials.gov registry entry for NCT02253745 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (84% lower). The listed sponsor is Vernalis (R&D), which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02253745 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT02253745 about?

NCT02253745 is a clinical study titled "Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)". The purpose of this research study is to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of twice daily oral doses of V81444 in adults with ADHD. Pharmacokinetics (PK) is the study of how a drug is absorbed, distributed, metabolized, and eventually eliminated by the body....

What is the current status of trial NCT02253745?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2013-07. Estimated completion is 2014-04.

What conditions does trial NCT02253745 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT02253745?

The interventions under investigation include: Placebo (DRUG), V81444 (DRUG).

Who is sponsoring clinical trial NCT02253745?

This trial is sponsored by Vernalis (R&D), which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02253745 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.